Eli Lilly Return On Equity vs. Shares Owned By Insiders

LLY Stock  USD 760.00  11.55  1.50%   
Based on the key profitability measurements obtained from Eli Lilly's financial statements, Eli Lilly's profitability may be sliding down. It has an above-average probability of reporting lower numbers next quarter. Profitability indicators assess Eli Lilly's ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
0.48648799
Current Value
0.26
Quarterly Volatility
0.4529705
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Eli Lilly's Price To Sales Ratio is fairly stable compared to the past year. EV To Sales is likely to rise to 16.84 in 2024, whereas Days Sales Outstanding is likely to drop 61.94 in 2024. At this time, Eli Lilly's Operating Income is fairly stable compared to the past year. Interest Income is likely to rise to about 204.8 M in 2024, whereas Accumulated Other Comprehensive Income is likely to drop (4.5 B) in 2024.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.620.8073
Way Down
Pretty Stable
Operating Profit Margin0.280.3026
Significantly Down
Slightly volatile
Pretax Profit Margin0.250.1921
Significantly Up
Very volatile
For Eli Lilly profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eli Lilly to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eli Lilly and utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eli Lilly's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eli Lilly and over time as well as its relative position and ranking within its peers.
  

Eli Lilly's Revenue Breakdown by Earning Segment

Check out Correlation Analysis.
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.664
Dividend Share
4.69
Earnings Share
6.76
Revenue Per Share
39.919
Quarterly Revenue Growth
0.26
The market value of Eli Lilly is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Eli Lilly Shares Owned By Insiders vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Eli Lilly's current stock value. Our valuation model uses many indicators to compare Eli Lilly value to that of its competitors to determine the firm's financial worth.
Eli Lilly and is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in shares owned by insiders category among related companies making about  0.32  of Shares Owned By Insiders per Return On Equity. The ratio of Return On Equity to Shares Owned By Insiders for Eli Lilly and is roughly  3.17 . At this time, Eli Lilly's Return On Equity is fairly stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Eli Lilly by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eli Lilly's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Eli Lilly's earnings, one of the primary drivers of an investment's value.

Eli Lilly's Earnings Breakdown by Geography

Eli Shares Owned By Insiders vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Eli Lilly

Return On Equity

 = 

Net Income

Total Equity

 = 
0.51
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Eli Lilly

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
0.16 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Eli Shares Owned By Insiders Comparison

Eli Lilly is currently under evaluation in shares owned by insiders category among related companies.

Eli Lilly Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Eli Lilly, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eli Lilly will eventually generate negative long term returns. The profitability progress is the general direction of Eli Lilly's change in net profit over the period of time. It can combine multiple indicators of Eli Lilly, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-4.3 B-4.5 B
Operating Income10.3 B10.8 B
Income Before Tax6.6 B3.5 B
Total Other Income Expense Net-3.8 B-3.6 B
Net Income5.2 B3.1 B
Income Tax Expense1.3 B810.6 M
Net Income Applicable To Common Shares7.2 BB
Net Income From Continuing Ops5.2 B4.4 B
Non Operating Income Net Other-288.8 M-274.4 M
Interest Income173.6 M204.8 M
Net Interest Income-312.3 M-327.9 M
Change To Netincome-601.6 M-571.5 M
Net Income Per Share 5.82  6.11 
Income Quality 0.81  0.85 
Net Income Per E B T 0.80  0.60 

Eli Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Eli Lilly. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eli Lilly position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eli Lilly's important profitability drivers and their relationship over time.

Use Eli Lilly in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eli Lilly position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eli Lilly will appreciate offsetting losses from the drop in the long position's value.

Eli Lilly Pair Trading

Eli Lilly and Pair Trading Analysis

The ability to find closely correlated positions to Eli Lilly could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eli Lilly when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eli Lilly - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eli Lilly and to buy it.
The correlation of Eli Lilly is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eli Lilly moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eli Lilly moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eli Lilly can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Eli Lilly position

In addition to having Eli Lilly in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Education Thematic Idea Now

Education
Education Theme
Companies involved in apprenticeship, education, tutoring, schooling, online universities, and other learning services. The Education theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Education Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Eli Lilly offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:
Check out Correlation Analysis.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
CEOs Directory
Screen CEOs from public companies around the world
To fully project Eli Lilly's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Eli Lilly at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Eli Lilly's income statement, its balance sheet, and the statement of cash flows.
Potential Eli Lilly investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Eli Lilly investors may work on each financial statement separately, they are all related. The changes in Eli Lilly's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Eli Lilly's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.